ytb323,rapcabtagene autoleucel
novartis
['ytb323', 'lymsm', 'rapcabtagene', 'dlbcl']
rapcabtagene autoleucel, a novel car t cell therapy, was promisingly effective and tolerable in patients with relapsed/refractory dlbcl, according to findings from a phase 1 dose-escalation study. #lymsm #ash22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.